Form 4: QuidelOrtho Corp: CFO Busky Receives Amended Stock Option Grant
SEC Form 4
Chief Financial Officer Joseph M. Busky's stock options were amended to remove performance conditions and vest fully on December 31, 2023, subject to continued service.
Summary
- Joseph M. Busky, CFO of QuidelOrtho Corp, had his stock options amended on January 30, 2023.
- The amendment removed performance conditions previously attached to the options.
- The options will now vest in full on December 31, 2023, contingent on Busky's continued service with the company.
- Busky was granted 21,012 non-qualified stock options with an exercise price of $119.06.
- The options, originally granted on July 7, 2020, expire on July 7, 2030.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reports a standard update to executive compensation. The removal of performance conditions could be seen as slightly positive for the executive.
Positives
- The removal of performance conditions could be seen as a positive for Busky, as it simplifies the vesting requirements.
Future Outlook
The stock options will vest on December 31, 2023, contingent on Busky's continued service.
Industry Context
Stock option grants and amendments are common practices in executive compensation packages to incentivize performance and retain key personnel.
Comparison to Industry Standards
- Executive compensation packages, including stock options, vary significantly across the diagnostics and healthcare industry.
- Companies like Abbott Laboratories, Danaher Corporation, and Roche typically use a mix of salary, bonus, and equity-based compensation to attract and retain top talent.
- The specific terms of stock option grants, such as vesting schedules and performance conditions, are often tailored to the individual executive and the company's strategic goals.
Stakeholder Impact
- Shareholders may view the amendment as a way to retain key management personnel.
- Employees may see this as a standard part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 07/07/2020 | Original grant date of the stock options |
| 01/30/2023 | Date of amendment to the stock option terms |
| 12/31/2023 | New vesting date for the stock options |
| 07/07/2030 | Expiration date of the stock options |
| 07/01/2024 | Date of signature on the form |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.